Use of $^{18}$F-FET PET in pediatric brain tumors

The usefulness of dynamic $O$-(2-$[^{18}$F]fluoroethyl)-L-tyrosine-PET in the clinical evaluation of brain tumors in children and adolescents

Veronika Dunkl$^{1,2}$, Corvin Cleff$^{2}$, Gabriele Stoffels$^{1}$, Natalie Judov$^{1}$, Sevgi Sarikaya-Seiwert$^{3}$, Ian Law$^{4}$, Lars Bøgeskov$^{5}$, Karsten Nysom$^{6}$, Sofie B. Andersen$^{4}$, Hans-Jakob Steiger$^{3}$, Gereon R. Fink$^{1,2}$, Guido Reifenberger$^{7}$, Nadim J. Shah$^{1}$, Heinz H. Coenen$^{1}$, Karl-Josef Langen$^{1,8}$, and Norbert Galldiks$^{1,2,9}$

$^{1}$Inst. of Neuroscience and Medicine, Research Center Jülich, Jülich, Germany

$^{2}$Dept. of Neurology, University of Cologne, Cologne, Germany

$^{3}$Dept. of Neurosurgery, Heinrich Heine University Düsseldorf, Düsseldorf, Germany

Depts. of $^{4}$Clinical Physiology, Nuclear Medicine & PET, $^{5}$Neurosurgery, $^{6}$Pediatrics and Adolescent Medicine, Rigshospitalet Copenhagen, Denmark

$^{7}$Dept. of Neuropathology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany

$^{8}$Department of Nuclear Medicine, University of Aachen, Aachen, Germany

$^{9}$Center of Integrated Oncology (CIO), University of Cologne, Cologne, Germany

Running title:

$^{18}$F-FET PET in pediatric brain tumors

To be submitted to the

Journal of Nuclear Medicine
Use of $^{18}$F-FET PET in pediatric brain tumors

Correspondence:
Norbert Galldiks, M.D.
Institute of Neuroscience and Medicine
Research Center Jülich
52425 Jülich
Germany
Phone: +49-2461-61-9324
FAX: +49-2461-61-1518
Email: n.galldiks@fz-juelich.de

Conflict of Interest
G.R. has received a research grant from Roche and honoraria for advisory boards from Roche, Merck-Serono and Amgen. The other authors declare that they have no conflict of interest.
ABSTRACT

Experience regarding \(O-(2-[^{18}\text{F}]\text{-fluoroethyl})\)-L-tyrosine (\(^{18}\text{F}\)-FET) PET in children and adolescents with brain tumors is limited. **Methods:** Sixty-nine \(^{18}\text{F}\)-FET PET scans of 48 children and adolescents (median age, 13 years; range, 1-18 years) were analyzed retrospectively. Twenty-six scans were performed to assess newly diagnosed cerebral lesions; 24 scans for diagnosing tumor progression/recurrence; 8 scans for monitoring of chemotherapy effects; and 11 scans for the detection of residual tumor after resection. Maximum and mean tumor/brain ratios (TBR\(_{\text{max/mean}}\)) were determined at 20-40 min p.i. and time-activity curves of \(^{18}\text{F}\)-FET uptake were assigned to three different patterns: (1) constant increase; (2) peak at > 20-40 min p.i. followed by a plateau; and (3) early peak (\(\leq\) 20 min) followed by a constant descent. Diagnostic accuracy of \(^{18}\text{F}\)-FET PET was assessed by receiver-operating-characteristic (ROC) curve analyses using histology and/or clinical course as reference. **Results:** In patients with newly diagnosed cerebral lesions, highest accuracy (77%) to detect neoplastic tissue (19 of 26 patients) was obtained when TBR\(_{\text{max}}\) was \(\geq 1.7\) (AUC, 0.80±0.09; sensitivity, 79%; specificity, 71%; PPV, 88%; \(P=0.02\)). For diagnosing tumor progression/recurrence, highest accuracy (82%) was obtained when curve patterns 2 or 3 were present (AUC, 0.80±0.11; sensitivity, 75%; specificity, 90%; PPV, 90%; \(P=0.02\)). During chemotherapy, a decrease of TBRs was associated with a stable clinical course and in two patients, PET detected residual tumor after presumably complete tumor resection. **Conclusions:** Our findings suggest that \(^{18}\text{F}\)-FET PET can add valuable information for clinical decision-making in pediatric brain tumor patients. **Keywords:** glioma; kinetic pattern of \(^{18}\text{F}\)-FET uptake; metabolic imaging; contrast-enhanced MRI; children; FET PET **Word Count:** 5143
INTRODUCTION

Primary tumors of the central nervous system (CNS) are one of the most common causes of cancer-related death in children ([1]). The choice of antitumoral treatment depends upon tumor histology, tumor location and patient age and management of CNS tumors in this patient group to date remains challenging. Brain tumors in children and adolescents comprise a great variety of tumor entities of varying malignancy, such as pilocytic astrocytoma, diffuse astrocytic gliomas including glioblastoma, ependymoma, medulloblastoma and other CNS primitive neuroectodermal tumor types, as well as various other tumor types, e.g., craniopharyngioma and germ cell tumors. Tumor location is heterogeneous, and in many cases, proximity to critical or eloquent brain structures precludes complete and partial resection and allows for diagnostic (stereotactic) biopsy only.

Concerning diagnostic imaging, contrast-enhanced structural MRI alone cannot always distinguish neoplastic from benign intracranial lesions. Moreover, the differentiation of treatment effects, such as, e.g., radiation-induced changes, from recurrent and/or progressive disease may be difficult. In adult patients, PET using radiolabeled amino acids has been shown to improve diagnostic accuracy in patients with primary brain tumors, in particular gliomas (2, 3). In pediatric brain tumor patients (4-6), several studies suggest that amino acid PET with the tracer methyl-[11C]-L-methionine (11C-MET) may improve the management. Results of these studies also implicate that 11C-MET PET might be useful to differentiate neoplastic from non-neoplastic lesions in children and adolescents, in particular when a definite decision for further treatment based upon routine structural MR imaging procedures alone is difficult or impossible. Unfortunately, however, the use of 11C-MET is limited to PET centers with a cyclotron on site because of the short half-life of 11C (20 min) (7).
O-(2-[18F]-fluoroethyl)-L-tyrosine ([18F]-FET) is a well-established [18F]-labeled amino acid for PET (half-life, 109 min) and offers logistic advantages over [11C]-MET for clinical practice (8, 9). Investigations of adult brain tumor patients with PET using [11C]-MET and [18F]-FET have reported comparable results for the two tracers (10). The evaluation of time-activity-curves (TAC) of [18F]-FET PET uptake may, however, provide valuable additional diagnostic information due to differential kinetic patterns of tracer uptake in high- and low-grade glioma (11-13), a phenomenon not observed with [11C]-MET PET (14). For example, the kinetic pattern of a high-grade glioma appears to be characterized by an early peak after injection within the first 20 min followed by a decrease of [18F]-FET uptake. In contrast, steadily increasing time-activity curves without identifiable peak of the tracer uptake are typical for low-grade gliomas (12, 13, 15-19).

To date, experience with dynamic [18F]-FET PET in children and adolescents with brain tumors is limited and is based on single case reports (20-22). Thus, the purpose of this study was to evaluate the diagnostic accuracy of this method in this particular age group.
Use of $^{18}$F-FET PET in pediatric brain tumors

MATERIALS AND METHODS

Ethics
This study represents a retrospective evaluation of a series of medically necessary $^{18}$F-FET PET investigations in children and adolescents that were performed as compassionate use. The study was approved by the local ethics committee. There was no conflict with the declaration of Helsinki. All investigations were carried out on the expressed request and written documentation of the responsible pediatricians and in full agreement with the legal guardians. In all cases, there was no further diagnostic alternative except potentially life-threatening invasive procedures. Based on the clinical experience in several thousand $^{18}$F-FET PET investigations in adult patients without any side effects and based on the fact that no side effects or risks (except radiation burden) were to be expected due to the extremely low concentration of this non-toxic artificial amino acid, the risk of disease was judged as outweighing the risk of investigation.

Patients
Forty-eight children and adolescents $\leq 18$ years of age with brain tumors who had received dynamic $^{18}$F-FET PET scans at the Research Center Jülich, Germany, and Rigshospitalet Copenhagen, Denmark, between the years 2006 and 2012 were identified retrospectively. All patients had been referred consecutively because decision making for further diagnostic procedures or treatment planning was difficult based on the clinical presentation and/or MRI findings alone. The patients had been referred for $^{18}$F-FET PET imaging for assessment of newly diagnosed cerebral lesions ($n=26$ scans in 26 patients); for diagnosing possible tumor progression or recurrence of previously diagnosed brain tumors ($n=24$ scans in 18 patients); for monitoring of chemotherapy effects ($n=8$ scans in 4 patients); and for the detection of residual tumor tissue after
Use of $^{18}$F-FET PET in pediatric brain tumors

resection (n=11 scans in 10 patients). Eight patients were examined for more than one indication. At the time of initial diagnosis, the median age of the patients was 13 years (range, 1-18 years; 21 male, 28 female patients). The purpose of the scan as well as potential risks were explained to the patients and their legal guardians before they signed a document of informed consent prior to each $^{18}$F-FET PET examination as part of clinical routine. A total of 69 $^{18}$F-FET PET scans were performed on the entire cohort of patients (n=48). In patients with newly diagnosed cerebral lesions, $^{18}$F-FET PET was performed within the first 6 weeks after initial diagnosis. In patients with suspected tumor progression/recurrence, the time between initial diagnosis and $^{18}$F-FET PET imaging was 24 ± 35 months (range, 1-159 months; median, 12 months).

As reported before, the threshold of age to differentiate between children and adolescents was set at 15 years (4). In the literature, a clear definition of an adolescent is not available; therefore, the threshold of 15 years was set in the middle of the period of life between 10 and 20 years, which is the current definition of adolescence by the World Health Organization (WHO). At the time of $^{18}$F-FET PET imaging, 35 of the 48 patients (73%) studied were younger than 15 years.

**PET Imaging with $^{18}$F-FET and Data Analysis**

The amino acid $^{18}$F-FET was produced via nucleophilic $^{18}$F-fluorination with a specific radioactivity of $>200$ GBq/$\mu$mol as described previously (23). The radiochemical yield of the tracer was about 60–65% at a radiochemical purity $>98\%$. The tracer was administered as isotonic neutral solution. All patients remained fasted for at least 6 h before PET scanning. Dynamic PET studies were acquired up to 50 min after intravenous injection of $^{18}$F-FET on an ECAT EXACT HR+ scanner (Siemens Medical Systems, Inc.) (32 rings; axial field of view, 15.5 cm) or on a Siemens Biograph Truepoint PET/CT scanner (4 rings; axial field of view, 21.8 cm)
Use of $^{18}$F-FET PET in pediatric brain tumors

in 3-dimensional mode. The dose of the injected radionuclide was adjusted for body weight (24). In addition, in children sedation or even general anesthesia especially in very young children was necessary to avoid patient movement. The emission recording consisted at least of 16 time frames covering the period up to 50 min post injection. For attenuation correction, transmission was measured with $3^{68}$Ge/$^{68}$Ga rotating line sources or a CT-based attenuation correction was used. After correction for random and scattered coincidences and dead time, images were filtered with a 5 mm FWHM Gaussian filter. Image data were iteratively reconstructed (at least 40 image planes, 4 iterations and 12 subsets). The reconstructed image resolution was approximately 6.4 mm. $^{18}$F-FET uptake in the tissue was expressed as standardized uptake value (SUV) by dividing the radioactivity (kBq/mL) in the tissue by the radioactivity injected per gram of body weight.

$^{18}$F-FET PET and, whenever available, contrast-enhanced MRI were co-registered using the MPI tool software (MPI tool version 6.48; ATV, Kerpen, Germany). The fusion results were inspected and, if necessary, adapted based on anatomic landmarks. The Regions-of-Interest (ROI) analysis was based on the summed PET data from 20-40 min post injection (25). The transaxial slices showing the highest $^{18}$F-FET accumulation in the tumors were chosen for ROI analyses. $^{18}$F-FET uptake in the unaffected brain tissue was determined by a larger ROI placed on the contralateral hemisphere in an area of normal appearing brain tissue including white and gray matter (25). $^{18}$F-FET uptake in the tumor was determined using a two-dimensional autocontouring process using a tumor-to-brain ratio (TBR) $\geq 1.6$. This cut-off is based on a biopsy-controlled study in cerebral gliomas where a lesion-to-brain ratio of 1.6 separated best tumoral from peritumoral tissue (26). When $^{18}$F-FET uptake of the lesion was similar to that of normal brain tissue, a representative irregular ROI was placed manually on the area of signal abnormality in the T1- and T2-weighted transversal MR scan and transferred to the coregistered $^{18}$F-FET PET scan (2).
Mean and maximum TBR (TBR$_{\text{mean}}$ and TBR$_{\text{max}}$) were calculated by dividing the mean and maximum SUV of the tumor ROI by the mean SUV of normal brain tissue in the $^{18}$F-FET PET scan. TACs of mean SUV in the tumor and in the normal brain tissue were generated by applying these ROIs to the entire dynamic data set. Time-to-peak (TTP; time in minutes from the beginning of the dynamic acquisition up to the maximum SUV of the lesion) was determined in the ROI of the tumor. As described previously (18), TACs of each lesion were assigned to one of the following curve patterns: (1) constantly increasing $^{18}$F-FET-uptake without identifiable peak uptake during data acquisition; (2) $^{18}$F-FET-uptake peaking at a midway point (> 20-40 min) followed by a plateau; and (3) $^{18}$F-FET-uptake peaking early (≤ 20 min) followed by a constant descent (Figure 1A-C).

**Statistical Analysis**

Descriptive statistics are provided as mean and standard deviation. To compare two different groups, the Student $t$ test for independent samples was used. The Mann-Whitney rank sum test was used when variables were not distributed normally. $P$ values of less than 0.05 were considered significant.

The diagnostic accuracy of the TBR$_{\text{mean}}$ and TBR$_{\text{max}}$ of $^{18}$F-FET uptake for differentiation of neoplastic lesions from non-neoplastic lesions in patients with newly diagnosed cerebral lesions and for differentiation of tumor progression or recurrence from unspecific posttherapeutic changes was evaluated by receiver-operating-characteristic (ROC) curve analyses using histological diagnosis and/or the clinical follow-up as reference. The decision cut-off was considered optimal when the product of paired values for sensitivity and specificity reached its
maximum. In addition, the area under the ROC curve (AUC), its standard deviation, and the level of significance were determined as a measure of the diagnostic quality of the test. The diagnostic performance of curve patterns alone and in combination with TBRs was evaluated by Fisher exact test for 2 x 2 contingency tables.

Statistical analysis was performed using SigmaPlot software (SigmaPlot Version 11.0, Systat Software Inc., San Jose, CA) and PASW Statistics software (Release 22.0.0, SPSS Inc., Chicago, IL, USA).
RESULTS

Patients with Newly Diagnosed Cerebral Lesions

In the 26 patients with newly diagnosed cerebral lesions, a total of 26 PET scans were performed. The diagnoses in the 26 patients with newly diagnosed cerebral lesions originally suggestive of neoplastic lesions/glioma were distributed as follows: WHO grade I dysembryoplastic neuroepithelial tumor (n=1), WHO grade I pilocytic astrocytoma (n=2), WHO grade II diffuse astrocytoma (n=4), WHO grade III anaplastic astrocytoma (n=4), WHO grade IV glioblastoma (n=4), demyelinating lesion compatible with multiple sclerosis (n=1), ischemic lesion/stroke (n=1), arteriovenous vascular malformation (n=1), low-grade glioma, WHO grade histologically not specified (n=3), Rathke’s cyst (n=1), and hyperintense MRI lesions on T2-/FLAIR-weighted images without histological confirmation (n=4), one of which was confirmed as being due to a neoplastic lesion while 3 were proven as non-neoplastic lesions on follow-up (Supplemental Table 1). Diagnoses were confirmed histologically in 20 of 26 patients (77%). In 6 patients the diagnosis of a brain tumor / benign lesion was determined clinically (i.e., stable/unstable clinical course, follow-up MRI findings).

In this group of patients with newly diagnosed cerebral lesions, ROC analysis revealed that the highest accuracy (77%) to detect neoplastic tissue (19 of 26 patients) was obtained when TBR$_{\text{max}}$ was $\geq 1.7$ (AUC, 0.80 $\pm$ 0.09; sensitivity, 79%; specificity, 71%; PPV, 88%; $P = 0.02$) (Supplemental Table 5). A corresponding patient example is presented in Figure 1A. The diagnostic accuracy was slightly lower when the TBR$_{\text{mean}}$ was used as a parameter. The inclusion of kinetic parameters yielded no significant result regarding the differentiation of neoplastic from non-neoplastic lesions.
Patients with Suspicion of Tumor Progression or Recurrence

Eighteen patients with suspected tumor progression or recurrence underwent a total of 24 PET examinations. The histologically confirmed initial diagnoses in patients with suspected tumor progression or recurrence (n=18) were distributed as follows: WHO grade I pilocytic astrocytoma (n=2), WHO grade II diffuse astrocytoma (n=2), WHO grade III secondary anaplastic astrocytoma after malignant progression (n=1), WHO grade II oligodendroglioma (n=1), WHO grade III oligoastrocytoma (n=1), WHO grade II ependymoma (n=1), WHO grade III ependymoma (n=2), WHO grade II pleomorphic xanthoastrocytoma (n=1), WHO grade IV medulloblastoma (n=1), WHO grade IV glioblastoma (n=5), and malignant melanoma metastasis (n=1). In 5 of these 18 patients, two or more PET scans were performed (range of PET scans, 2-3). The diagnosis of presence or absence of tumor progression/recurrence was confirmed histologically in 5 of 18 patients (28%; Supplemental Table 2). In 13 patients absence or presence of tumor progression/recurrence was determined clinically (i.e., stable/unstable clinical course, follow-up MRI findings, overall survival, treatment change) (Supplemental Table 2). In 13 of 24 cases, tumor progression or recurrence could be diagnosed.

For diagnosing tumor progression or recurrence, a high diagnostic accuracy was achieved when the TBR$_{\text{mean}}$ and TBR$_{\text{max}}$ were used (79%). Highest accuracy (82%) was, however, obtained when decision was based on kinetic parameters, i.e., when curve patterns 2 or 3 were present (sensitivity, 75%; specificity, 90%; PPV, 90%; $P = 0.004$) (Supplemental Table 5). A corresponding patient example is presented in Figure 1B and 1C.

Use of $^{18}$F-FET PET for Monitoring of Chemotherapy Effects
In 4 patients with WHO grade IV tumors, $^{18}$F-FET PET was used to monitor chemotherapy effects (Supplemental Table 3). Compared to baseline PET, in all patients a decrease of both $\text{TBR}_{\text{max}}$ (range of highest $\text{TBR}_{\text{max}}$ decrease, 21-33%) and $\text{TBR}_{\text{mean}}$ (range of highest $\text{TBR}_{\text{mean}}$ decrease, 10-24%) could be observed. During chemotherapy, a decrease of TBRs was associated with a stable clinical course for at least 6 months. Additionally, in 3 of 4 patients a change of the kinetic pattern (from pattern 2 or 3 to pattern 1) and a prolongation of TTP values (range, 15-35 min) were present. A complete response according to Macdonald criteria (27) as assessed by contrast-enhanced follow-up MRI could not be observed.

Use of $^{18}$F-FET PET for the Detection of Residual Tumor Tissue After Resection

In order to detect residual tumor tissue after tumor resection, 10 patients were investigated by early postoperative MRI within the first 48 h and $^{18}$F-FET PET (median time after resection, 7 d; range, 2-36 d) (Supplemental Table 4). One patient (patient ID 29) underwent surgery twice and was, therefore, examined twice. In one patient the postoperative MRI, however, was not available (patient ID 16). Seven patients had high-grade tumors (WHO grade III or IV), the remaining 3 patients had low-grade tumors (WHO grade I or II). The early postoperative MRI yielded presence of contrast enhancement or non-enhancing tumor mass in 8 patients (considered as partial resection) and absence thereof in one patient (considered as complete resection). In patients with partial resection, $^{18}$F-FET PET detected metabolically active tumor ($\text{TBR}_{\text{max}} \geq 1.7$; Supplemental Table 4).
DISCUSSION

Our findings suggest that imaging parameters derived from $^{18}$F-FET PET may be helpful in pediatric patients with brain tumors, especially regarding the identification of newly diagnosed brain lesions suggestive of glioma and in the diagnosis of tumor progression/recurrence. Highest diagnostic accuracy (range, 73-77%) was achieved by the use of a simple threshold-based ROI approach in newly diagnosed lesions and by the analysis of the kinetic pattern of $^{18}$F-FET uptake in diagnosis of possible tumor progression or recurrence (82%). To the best of our knowledge, the present study evaluates for the first time dynamic parameters of $^{18}$F-FET uptake in brain tumors of pediatric and adolescent patients and provides similar results as previously observed in adult glioma patients (2, 3).

Furthermore, first experiences in a small number of pediatric brain tumor patients in our study demonstrate that $^{18}$F-FET PET may be helpful for monitoring the effects of chemotherapy in malignant brain tumors. In the majority of these patients treated with chemotherapy we observed a reduction of amino acid uptake. Our findings suggest that this finding is related to a stable clinical course. However, this observation should be re-evaluated in a higher number of pediatric patients with the same histology and chemotherapy. Moreover, $^{18}$F-FET PET appears to be helpful to determine the residual tumor volume after brain tumor resection and may serve as a valuable tool for optimal planning of the further treatment strategy, e.g., decision for re-resection, adjuvant radiotherapy. The reliability of $^{18}$F-FET PET to identify residual tumor after surgery has not yet been proven by a biopsy controlled study but previous studies using $^{11}$C-MET PET have demonstrated that amino acid PET is quite useful for this purpose (28). Nevertheless, to confirm these findings further studies are warranted.
Use of $^{18}$F-FET PET in pediatric brain tumors

To date, only a few amino acid PET studies have focused on children and adolescents with brain tumors, predominantly using PET with $^{11}$C-MET (4-6, 29). Pirotte and co-workers provided evidence that $^{11}$C-MET PET improves the diagnostic yield of stereotactic brain biopsies and surgical management of brain tumors in children (6, 30, 31). Consistent with this finding, a first study using stereotactic biopsy guided by metabolic imaging with $^{18}$F-FET PET enhanced the diagnostic yield in diffuse pediatric gliomas and disclosed unexpected “hot spots” (20). Despite these encouraging results, only a few experiences in children and adolescents with brain tumors using $^{18}$F-FET PET have been reported (21, 22). With regard to this important clinical issue, our findings suggest that valuable additional information can be derived from $^{18}$F-FET PET, which presents a rapidly developing new imaging method due to the logistical advantages compared with PET using $^{11}$C-MET.

In patients with newly diagnosed cerebral lesions suggestive of glioma (n=26), 15 of 19 brain tumors were correctly identified as neoplastic lesions. However, 2 of 7 benign lesions (i.e., an ischemic lesion and an demyelinating lesion) were wrongly classified as brain tumors, i.e., false positive. In adults, moderate $^{18}$F-FET uptake has been reported previously in inflammatory brain lesions and in the vicinity of cerebral ischemia, brain abscesses, and cerebral hemorrhage, which appears to result from tracer uptake in reactive gliosis (32-36). Therefore, it seems likely that the evaluation of pediatric brain tumors by $^{18}$F-FET PET may be affected negatively in the same way.

Currently, the relevance for the clinical use of dynamic $^{18}$F-FET PET is still a matter of debate. Dynamic $^{18}$F-FET imaging requires longer acquisition times (50 min vs. 20 min), which reduces the number of patients who can be investigated with one synthesis or delivery of $^{18}$F-FET. This
Use of $^{18}$F-FET PET in pediatric brain tumors

increases the costs of the investigation in routine clinical practice. Furthermore, the shorter acquisition time is more comfortable for the patients and reduces motion artifacts and, in younger children, duration of sedation or anesthesia. On the other hand, in 18 patients with suspected tumor progression/recurrence 24 PET examinations were performed and the highest diagnostic accuracy (82%) could be obtained by the evaluation of curve patterns.

Furthermore, it should be noted that the differentiation between high- and low-grade glioma using amino acid PET is difficult. In children, a considerable overlap of amino acid uptake has been observed in low-grade and high-grade tumors (4, 5). Similar to glucose metabolism (37), amino acid uptake may be high in low-grade tumors like pilocytic astrocytoma and ganglioglioma, while uptake may be relatively low in patients with medulloblastoma of WHO grade IV (5).

One may argue that the results of our study are based upon a relatively small number of investigated patients with a large variety of distinct entities and that our results should hence be treated with caution and confirmed in a larger series of patients. However, the results of this study are based on 48 patients and 69 observations which constitutes to date the largest sample of children or adolescents brain tumors studied using static and dynamic $^{18}$F-FET PET, and the results are promising. With this caveat in mind, we thus recommend the use $^{18}$F-FET PET as an additional diagnostic tool in children and adolescents with brain tumors, especially when the diagnostic information derived from standard MR imaging is equivocal.

In the near future, the use of hybrid PET/MRI scanners may provide more comprehensive information. A first report of Garibotto and co-workers (21) supports the acquisition of both
Use of $^{18}$F-FET PET in pediatric brain tumors

Amino acid PET and MRI in a single session on a hybrid system in pediatric patients. Besides the valuable improvement of simultaneously acquired diagnostic information, especially in children, the use of this technology minimizes the patients’ discomfort (e.g., only a single transport to the imaging facility is necessary, resulting also in a substantial reduction of scanning time, avoidance of an additional sedation or general anesthesia by an anesthesiologist), and helps to optimize co-registration of both imaging modalities. However, the optimal strategy of MRI based attenuation correction has not been identified at this moment. The present standard is the Dixon water-fat segmentation (DWFS) method, that systematically ignores bone and metal implants [38]. The consequences for the distribution of metabolic activity need to studied in detail before the clinical use in pediatric neurooncology can be endorsed.

CONCLUSION

In summary, pediatric and adolescent patients with cerebral tumors, both standard and kinetic imaging parameters derived from $^{18}$F-FET PET may add valuable information for clinical decision-making, especially in the field of differential diagnosis of newly diagnosed brain lesions suggestive of glioma and in the identification of tumor progression or recurrence after specific neurooncological treatment.

ACKNOWLEDGEMENTS

The authors wish to thank Suzanne Schaden, Elisabeth Theelen, and Kornelia Frey for their gentle and compassionate care of the young patients and their parents as well as Johannes Ermert, Silke Grafmüller, Erika Wabbals, and Sascha Rehbein for radiosynthesis of $^{18}$F-FET. The Brain Imaging Center West supported this work.
REFERENCES


Use of $^{18}$F-FET PET in pediatric brain tumors


Use of $^{18}$F-FET PET in pediatric brain tumors


Use of $^{18}$F-FET PET in pediatric brain tumors


Use of $^{18}$F-FET PET in pediatric brain tumors


Use of $^{18}$F-FET PET in pediatric brain tumors


Figure 1: Patient examples with different kinetic patterns of $^{18}$F-FET uptake. T1-weighted MRI on the left, T2-/FLAIR-weighted MRI in the middle, $^{18}$F-FET PET on the right. Upper row (A): patient with a demyelinating lesion (i.e., multiple sclerosis) (patient ID 7) with moderately increased $^{18}$F-FET uptake and a curve pattern 1; middle row (B): recurrent glioblastoma (patient ID 26) with high $^{18}$F-FET uptake and a curve pattern 2; bottom row (C): anaplastic astrocytoma (patient ID 10) with moderately increased $^{18}$F-FET uptake and a curve pattern 3
The usefulness of dynamic O-(2-[18F]fluoroethyl)-L-tyrosine-PET in the clinical evaluation of brain tumors in children and adolescents


J Nucl Med.
Published online: December 18, 2014.
Doi: 10.2967/jnumed.114.148734

This article and updated information are available at: http://jnm.snmjournals.org/content/early/2014/12/16/jnumed.114.148734

Information about reproducing figures, tables, or other portions of this article can be found online at: http://jnm.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNM can be found at: http://jnm.snmjournals.org/site/subscriptions/online.xhtml

JNM ahead of print articles have been peer reviewed and accepted for publication in JNM. They have not been copyedited, nor have they appeared in a print or online issue of the journal. Once the accepted manuscripts appear in the JNM ahead of print area, they will be prepared for print and online publication, which includes copyediting, typesetting, proofreading, and author review. This process may lead to differences between the accepted version of the manuscript and the final, published version.

The Journal of Nuclear Medicine is published monthly.
SNMMI | Society of Nuclear Medicine and Molecular Imaging
1850 Samuel Morse Drive, Reston, VA 20190.
(Print ISSN: 0161-5505, Online ISSN: 2159-662X)

© Copyright 2014 SNMMI; all rights reserved.